BioAge Labs opened lower at $5.72, compared with its previous close of $5.87. In the last trading session, the stock traded between $5.47 and $5.87. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 3 years ago in BioAge Labs is now worth
$ 30.92
Resulting in a loss of
$ 69.08 (69.08%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 4 Analysts
Buy
75%
Hold
25%
Sell
0%
Markets Today
Today's Change
$-0.21 (-3.56%)
Day High
$5.87
Day Low
$5.47
Day Open
$5.72
Prev Close
$5.87
Volume
3,95,073
1W Return
-5.06%
1M Return
-4.78%
3M Return
-47.04%
6M Return
-68.83%
1Y Return
-27.70%
Fundamentals
Market Cap ($ Mn)
260
PE Ratio
-
PB Ratio
1.18
PEG Ratio
-
ROE
-27.22%
ROCE
-30.89%
EPS (TTM)
-
Investment Returns
1 Week
-5.06%
1 Month
-4.78%
3 Months
-47.04%
6 Months
-68.83%
9 Months
-71.68%
Financials
Quarterly
All values in $ Mn
1.5
Mar 25
2.4
Jun 25
2.1
Sep 25
3.1
Dec 25
2.5
Jun 26
0.3
Sep 26
Updates
6Nov
Bioage Labs Q3 Results: EPS loss widens to $0.73, sales fall 85%
Bioage Labs reported a loss of $(0.73) per share, missing the $(0.59) estimate by 23.73%. Quarterly sales dropped 85.49% YoY to $298.000 thousand, far below the $1.644 million forecast. The loss per share widened by 30.36% compared to the $(0.56) loss in the same quarter last year.
7 days ago
26Sep
BioAge Labs to present at ROTH and Stifel investor conferences in late September
BioAge Labs will attend ROTH Healthcare Opportunities Conference on Sept 29, 2026. Stifel Virtual Cardiometabolic Forum participation is scheduled for Sept 30, 2026. Lead candidate BGE-102 Phase 2 CV data expected in H2 2026. DME Phase 2 data from QUELL-DME anticipated in H2 2027.
1mo ago
6Aug
BioAge Labs Q2 EPS beats estimates as revenue rises 1.6%
BioAge Labs Inc. exceeded Q2 analyst expectations with EPS of $(0.58) and revenue of $2.451 million, beating estimates by 3.33% and 27.63% respectively. Despite a widened net loss of $26.1 million due to increased R&D for the BGE-102 program, the company maintains strong liquidity and advanced clinical trials.
3mo ago
31Jul
BioAge Labs stock plunges 61.73% after Novo Nordisk trial failure
BioAge Labs Inc. stock fell 61.73% to $9.51 as Novo Nordisk's failed Phase 3 trial raised doubts about NLRP3 therapies. William Blair maintained a Market Perform rating, citing high risk. Neumora Therapeutics also saw declines due to shared mechanism concerns.
